Key points
- FY26 revenue: $85,339 from first commercial sales
- Loss after tax: $5.93 million, up from $3.83 million
- Cash at 30 June: $3.36 million, up from $1.40 million
- Operating cash outflow: $5.23 million
- Net assets: $3.64 million
Full summary
Rhythm Biosciences Limited (ASX: RHY) has released its FY26 Appendix 4E and Audited Financial Report. The company reported a revenue of $85,339 from its first commercial sales. The loss after tax increased to $5.93 million from $3.83 million in the previous year, primarily due to people and commercialization costs. The company's cash position at 30 June 2026 was $3.36 million, up from $1.40 million in the previous year. The operating cash outflow was $5.23 million. Net assets stood at $3.64 million. FY2026 marked the transition from a development-stage business to a commercial diagnostics enterprise, with both diagnostic platforms, ColoSTAT® and geneType®, recording clinical sales. The company also strengthened its balance sheet through placements and options exercises.
Guidance
FY26 revenue: $85,339; Loss after tax: $5.93 million; Cash at 30 June: $3.36 million
Outlook
Rhythm Biosciences anticipates no unusual future events likely to significantly impact operations, results, or state of affairs. The company remains focused on commercializing ColoSTAT® and expanding its market presence.